Key result
Hematopoietic cell transplantation reduces mean ECV by ~3.4% in young SCD patients, indicating less diffuse fibrosis.
Why the study?
Does hematopoietic cell transplantation reduce diffuse myocardial fibrosis in children and young adults with sickle cell disease?
Does hematopoietic cell transplantation reduce diffuse myocardial fibrosis in children and young adults with sickle cell disease?
Hematopoietic cell transplantation is associated with a reduction in diffuse myocardial fibrosis in young patients with sickle cell disease at 12 months.
HCT-associated ECV reduction in young SCD patients; hypothesis-generating for outcomes and requires randomized confirmation before practice change.
Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2024) studied this question. Hematopoietic cell transplantation decreased mean ECV, representing diffuse myocardial fibrosis, by 3.4% at 12 months in young patients with sickle cell disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: